All In Biotech

Drug Trial Radar · NCT04447898

Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine

A Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Study Assessing the Safety and Immune Response of PPV-06 Vaccine in Patient With Inflammatory Knee Osteoarthritis (KOA)

Last checked: Nov 19, 2026Latest source record: May 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Feb 18, 2021

Primary completion

Feb 28, 2023

Study completion Feb 28, 2023

Sponsor

Lead sponsor
Peptinov SASIndustry
Sponsor type
Industry
First posted
Jun 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PPV-06 immunotherapy targets interleukin-6 (IL-6), a key molecule of the immune system whose overproduction is implicated in many inflammatory and autoimmune diseases such as rheumatoid arthritis and osteoarthritis. The benefit of vaccination with PPV-06 is to induce, in response to immunizations, the production of antibodies directed against IL-6. The antibodies produced will neutralize the biological activity of IL-6 involved in the body's inflammatory process. The primary objective is to evaluate the safety/tolerability of vaccination with PPV-06.

Conditions

  • Knee Osteoarthritis

Interventions

  • PPV-06 10 μgDrug

    Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112

  • PPV-06 50 μgDrug

    High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112

  • PlaceboDrug

    Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with DLT defined as grade 3 or higher treatment-related adverse events (monitored in all patients during the study treatment until the End of Study (Week 42) or early termination).Time frame: From Baseline to Week 42 (End of Study)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cic Cochin

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.